導脈順緩釋膠囊２．５毫克

Χώρα: Ταϊβάν

Γλώσσα: Κινεζικά

Πηγή: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Δραστική ουσία:

ISRADIPINE

Διαθέσιμο από:

臺灣諾華股份有限公司 台北市中正區仁愛路二段99號11、12、13樓 (01516589)

Φαρμακολογική κατηγορία (ATC):

C08CA03

Φαρμακοτεχνική μορφή:

持續性藥效膠囊劑

Σύνθεση:

ISRADIPINE (2412402100) 2.5MG

Μονάδες σε πακέτο:

盒裝

Kατηγορία:

製　劑

Τρόπος διάθεσης:

須由醫師處方使用

Κατασκευάζεται από:

NOVARTIS FARMACEUTICA S.A. RONDA SANTA MARIA,158,08210 BARBERA DEL VALLES BARCELONA,SPAIN ES

Θεραπευτική περιοχή:

isradipine

Θεραπευτικές ενδείξεις:

高血壓

Περίληψη προϊόντος:

註銷日期: 2016/02/15; 註銷理由: 自請註銷; 有效日期: 2016/08/02; 英文品名: DYNACIRC SRO CAPSULES 2.5MG

Καθεστώς αδειοδότησης:

已註銷

Ημερομηνία της άδειας:

1996-08-02

Φύλλο οδηγιών χρήσης

DYNACIRC SRO

Selective
calcium
channel
blockers
with
mainly
vascular
effects, dihydropyridine derivatives.
DESCRIPTION AND COMPOSITION
PHARMACEUTICAL FORMS
2.5 mg and 5 mg modified release capsules (SRO capsules)
for oral administration.
ACTIVE SUBSTANCE
Isradipine
Certain dosage strengths and dosage forms may not be
available in all countries.
EXCIPIENTS
DYNACIRC 2.5 MG SRO CAPSULES: Cellulose, microcrystalline;
cetyl palmitate; gelatine; iron oxide, black (only for Dynacirc
2.5
mg
SRO);
iron
oxide,
yellow;
magnesium
stearate;
hypromellose
shellac;
silica,
colloidal
anhydrous;
titanium
dioxide.
DYNACIRC 5 MG SRO CAPSULES: Cellulose, microcrystalline;
cetyl palmitate; gelatine; iron oxide, red (only for Dynacirc 5
mg
SRO);
iron
oxide,
yellow;
magnesium
stearate;
hypromellose
shellac;
silica,
colloidal
anhydrous;
titanium
dioxide.
INDICATIONS
Treatment of hypertension.
DOSAGE AND ADMINISTRATION
DYNACIRC SRO CAPSULES 2.5MG
The recommended dosage in mild to moderate hypertension
is 2.5 mg (one tablet) twice a day or one 5 mg SRO capsule
once a day.
DYNACIRC SRO CAPSULES 5MG
The recommended dosage in mild to moderate hypertension
is one 5 mg SRO capsule once a day.
Dynacirc SRO capsules must be swallowed whole.
If one 5 mg SRO capsule once a day is not sufficiently
effective, after at least 4 weeks of treatment, the addition of
another antihypertensive agent is recommended (preferably a
thiazide
diuretic,
ACE
inhibitor
or
beta-blocker).
Dynacirc
SRO
can
also
be
added
to
existing
antihypertensive
treatment. When Dynacirc SRO is given concurrently with
cimetidine, the dose of Dynacirc / Dynacirc SRO should be
reduced by 50% (see section INTERACTIONS).
SPECIAL POPULATIONS
Geriatrics, renal impairment and hepatic impairmentIn elderly
patients or in patients with impaired hepatic or renal function,
a more suitable starting dose is 1.25 mg (½ tablet) twice a
day or one 2.5 mg SRO capsule once a day.
Pediatrics
Well designed clinical trials of calcium channel blockers in
children
have
not
been
performed.
Although
limit